This drug targets aromatase, an enzyme that converts androgen to estrogen, and is amply used in endocrine receptor-positive breast cancer, since it significantly reduces serum estrogen levels, decreasing the activation of estrogen and progesterone receptors in breast cancer [11]. Here, CYP19A1 is linked to breast carcinoma.